RxDoctor Payments Data

Wanda Hu, MD

Ophthalmology · Sunnyvale, CANPI 1972803666

Payments from drug & device makers

$58,265in general payments, 2019–2025

Across 101 payments — averaging $576.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$48K
  • Aerie Pharmaceuticals, Inc.$9K
  • AbbVie$763
  • Amgen$439
  • Carl Zeiss Meditec USA, Inc.$294
  • Johnson & Johnson Surgical Vision, Inc.$148
  • plus $510 from 8 others

What the payments were for

  • Speaking & faculty fees$6,53061%
  • Travel & lodging$1,53414%
  • Food & beverage$2,29221%
  • Education$801%
  • Other$2943%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,265 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$486,689
Medicare patients
601
Services billed
3,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost81$55,411
LumiganBimatoprost85$46,862
VyzultaLatanoprostene Bunod57$25,844
RhopressaNetarsudil Mesylate54$25,398
SimbrinzaBrinzolamide/Brimonidine Tart61$18,692
XiidraLifitegrast12$17,215
Brinzolamide77$13,165
Prednisolone Acetate294$12,982
Latanoprost806$9,408
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol46$9,005
Cyclosporine11$6,430
CombiganBrimonidine Tartrate/Timolol16$6,282
Brimonidine Tartrate337$6,208
Difluprednate49$5,727
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat334$5,610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$8,559$80,809135 claims
AbbVieLumigan, Combigan$763$53,144101 claims
AlconSimbrinza$65$18,69261 claims
Thea Pharma Inc.Iyuzeh$14$4,44815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Sunnyvale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →